Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca and Circassia announce respiratory disease collaboration

AstraZeneca and Circassia announce respiratory disease collaboration

20th March 2017

AstraZeneca has announced a new collaboration with Circassia for the development and commercialisation of certain respiratory medicines.

Under the terms of the deal, Circassia will lead the promotion of the drug Tudorza in the US, in addition to securing an option to gain full commercial rights to the product in the future. Circassia has also been granted the rights to Duaklir in the US market.

AstraZeneca will continue ongoing development activities for the therapies and will continue to manufacture and supply both medicines, in return for a minority equity stake in the Circassia business.

Tudorza and Duaklir are both inhaled respiratory medicines for the treatment of chronic obstructive pulmonary disease. The former has been commercially available in the US in 2012, while the latter is expected to be submitted for US regulatory review next year.

Mark Mallon, executive vice-president for global product and portfolio strategy at AstraZeneca, said: "Tudorza and Duaklir are important components of AstraZeneca's respiratory franchise globally and this collaboration will support their commercialisation in the US for the benefit of the millions of COPD patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801833711-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.